by Raynovich Rod | Sep 26, 2012 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
Is There No End to the Biotech Bull Market? Biotech ETFs NASDAQ Biotechnology (IBB) up 36% YTD and NYSE (FBT) up 42% YTD Around 1998 I remember vividly two market conversations: one from a Sun Micro sales executive telling me “there is no end to chip...
by Raynovich Rod | Sep 25, 2012 | 2024-25 Life Science Portfolios, BIOgraph
Biotech Stocks Remain Resilient On A Bad Day The market took a nasty turn today with a 1.36% sell-off in NASDAQ and 1.05% for the S&P. The damage was across the board but the healthcare sector rose above the flack down only 0.11%. Large cap drug and...
by Raynovich Rod | Sep 17, 2012 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
The ETF IBB (142.62) hit an all time high today and is up 36.6% YTD. The low for IBB over two years was August 19, 2011 at $88.50. Our mid-cap biopharma index is up 0.8% with big winners in JAZZ ($54.65) and Exelixis (EXEL $5.40) and Medivation (MDVN $106.27)....
by Raynovich Rod | Sep 17, 2012 | BIOgraph, Biopharmaceuticals, Reading List
The MASS Biotechnology industry has crossed $6B as a 25 year effort beginning in 1985 with the MASS Biotechnology Council. Several major biotechnology companies were created around this time such as Biogen(BIIB) and Vertex (VRTX) as well as major venture capital...
by Raynovich Rod | Sep 14, 2012 | BIOgraph, Clinical Diagnostics and Tools, Macro
FED Policy Boosts Risk Assets -QQQs Should Outperform IBB We expect the biotech sector to slightly underperform NASDAQ (QQQ $70.22) in light of “QE Forever” yesterday and the shift to financials, materials, tech and other risk assets. Prior to yesterday...
by Raynovich Rod | Sep 13, 2012 | BIOgraph, Macro
Gold, financials, energy and materials soar-Gold up $34 to $1767 You have been hearing about the FED and QE for weeks now and today announced a $40B/month purchase of mortgage securities and after a slight delay the bull market roared ahead. Interest rates will be...
by Raynovich Rod | Sep 3, 2012 | BIOgraph, Biopharmaceuticals
Valuations Don’t Matter-Institutional Holders Are the Drivers Medivation (MDVN $105.65) sold off 3 pts Friday on modest volume today as profit taking ensued after the big run-up from the high 95. With a market cap of $3.89B the sales of the FDA approved drug...
